This page shows what was measured, who it was measured in, and what that does not settle.
What Valsartan does in the body
Hypertension, to lower blood pressure
From the FDA-approved label: Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Diovan (valsartan) blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT 1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Its action is therefore independent of the pathways for angiotensin II synthesis.
What happened in people
RNAWiki has not yet published a reviewed conclusion for this use.
§ A fixed RNAWiki sentence
Where this came from
Wording RNAWiki always uses, not a finding about this substance.
No reviewed claim names a result for any goal on this record.
No source is stored against this line.
The limit that matters most
Not recorded.
Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
What the registries record it as
The substance registry classes this as chemical.
FDA substance registry · 80M03YXJ7I · read 2026-08-29
Its recorded molecular formula is C24H29N5O3, weighing 435.52.
US prescribing information · 9402b022-5809-4251-dfef-54f6ef5723fe · read 2026-08-30
Where each sentence above came from
No recorded sentence describes the change this makes in a way that stands on its own. The page opens with what it is taken for instead, and the recorded explanation follows below.
Shown as the opening line on this page.
No statement of the main limit is recorded.
The four opening statements run to 117 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Stand-in result
A stand-in result is a number measured because the real result takes too long.
A picture of it, and where the picture fails
It is like judging a journey by the speedometer rather than by arriving.
Where that stops being true. Speed does predict arrival. Many stand-in results do not predict the real one.
What people get wrong. A stand-in result is often reported as the result itself.
A surrogate endpoint substituted for a clinical endpoint, valid only where the substitution has been shown to hold.
Formulation
A formulation is the exact made-up form a substance comes in.
A picture of it, and where the picture fails
It is like the difference between a whole bean and instant coffee.
Where that stops being true. Coffee tastes different. A formulation can change how much reaches the blood.
What people get wrong. Two products with the same name are assumed to behave the same. They often do not.
The specific composition and physical form of a product, including salt, excipients and release profile.
Receptor
A receptor is a part of a cell that a signal fits into.
A picture of it, and where the picture fails
A receptor is like a lock waiting for one key.
Where that stops being true. A lock either opens or does not. A receptor can be half-triggered, or worn out.
What people get wrong. Fitting a receptor is read as causing a benefit. It causes a step, and nothing more.
A protein that binds a specific ligand and converts that binding into a cellular response.
Pathway
A pathway is a chain of steps inside a cell, each one setting off the next.
A picture of it, and where the picture fails
A pathway is like a row of dominoes.
Where that stops being true. Dominoes fall one way. Pathways loop back and can switch themselves off.
What people get wrong. Changing one step is read as changing the outcome. Other steps often absorb it.
An ordered series of molecular interactions producing a defined cellular change.
What happened in people◇Read from sources, not yet reviewed
What was measured, goal by goal
One row for each goal a registered study measured something for. One column for each kind of thing that could be measured.
Registered studies list 40 outcome measures that RNAWiki could read. A registered study says what someone planned to measure. It does not say what they found. 0 of the matched studies tested this substance, and 0 posted a result.
There is no single score. A strong test result and a weak life result are different facts.
Goals down the side, kinds of measurement across the top. Each cell says what kind of thing was registered, not what was found.
Goal
Life outcome
What a body can do
How a person feels
A test result
A step in the body
Harms
How long
Who was studied
Cholesterol
∅Nothing in the sources checkedNo registered study lists a life outcome for this goal.
∅Nothing in the sources checkedNo registered study lists a performance measure for this goal.
∅Nothing in the sources checkedNo registered study lists a symptom measure for this goal.
△Only a number moved1 registered test measure.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Which registered measures put each goal on this table
Cholesterol
myocardial triglyceride levels
Sorted by fixed word lists, version v1. A name the rules do not recognise stays unsorted rather than moving to the nearest column.
What each mark on this table means
∅ Nothing in the sources checked
No registered study lists a life outcome for this goal.
△ Only a number moved
1 registered test measure.
— Not recorded
Harms were not a registered measure for this goal.
… Waiting for a reviewer
Who was studied is listed further down the page.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
Population blood pressure control
✗ The study did not show it
Who was studied
NCT05609513
How many people
87421
Study design
Not applicable
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
To evaluate the impact of circadian time of treatment in cardiovascular, cerebrovascular, metabolic, and renal risk assessment.
✗ The study did not show it
Who was studied
NCT00741585
How many people
21983
Study design
Phase 4
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
All-cause mortality
✗ The study did not show it
Who was studied
NCT02735707
How many people
20000
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Composite cardiac event (mostly myocardial infarction and heart failure hospitalization)
✗ The study did not show it
Who was studied
NCT06395194
How many people
15313
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial.
✗ The study did not show it
Who was studied
NCT00000620
How many people
10251
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Percentage of Patients Reaching the Endpoint: Progression to Diabetes - Valsartan Versus Non-valsartan
✗ The study did not show it
Who was studied
NCT00097786
How many people
9306
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What happened in people◇Read from sources, not yet reviewed
How close this is to real life
The top step is something a person would feel or care about. The bottom is a guess from software. Filled steps are where evidence exists for this substance.
■Living longer, or avoiding a major eventEvidence recorded. Death, a heart attack, a stroke, a hospital stay.2 registered measures of this kind. 2 written-up studies measured this and did not show a benefit.
□What a body can do day to dayNo evidence recorded. Walking, dressing, breathing, recovering.No registered study measures this.
□Measured performanceNo evidence recorded. How much was lifted, how far was run, how fast.No registered study measures this.
□Symptoms and quality of lifeNo evidence recorded. Pain, tiredness, mood, sleep, as the person rated it.No registered study measures this.
■A number that stands in for healthEvidence recorded. Cholesterol, blood sugar, bone density. A stand-in, not the thing itself.22 registered measures of this kind.
■A step measured inside a personEvidence recorded. Something measured in human tissue or human cells.A human record sits on the stored organism ladder.
■AnimalsEvidence recorded. Mice, rats, dogs. Useful for ideas, not proof about people.Stored records in Mouse, Rat, Dog. A result in animals says what to test next. It does not say what happens in people.
■Cells in a dishEvidence recorded. Cells or chemistry on a bench, far from a whole body.Stored mechanism abstracts describe steps measured in cells or tissue.
□A guess from softwareNo evidence recorded. Nobody measured it. RNAWiki never publishes one as a finding.RNAWiki stores no prediction for this record. Software can suggest a link. RNAWiki does not publish one as a finding.
Higher on these steps means closer to something a person would feel. It does not mean better done.
What it would be like to take◇Read from sources, not yet reviewed
Felt, measured, or meaningful
Three different things that get called the same word. Registered studies measured all three, and mixing them is how a blood test becomes a health claim.
Felt
Things a person could notice without a test.
No registered study measured anything of this kind.
Measured
Things only a test, a scale or a device shows.
blood pressure
urinary albumin excretion after 30 weeks
systolic blood pressure after 4 weeks
urine protein excretion after 20 weeks
systolic 24 hour blood pressure after 12 weeks
blood pressure less than 140/90 after 14 weeks
diastolic blood pressure after 8 weeks
sitting diastolic blood pressure after 8 weeks
mean sitting diastolic blood pressure at trough
urinary protein loss whithin 24 hours
and 12 more.
Meaningful
Things that change how a life goes, not only a number.
stroke
prevention of recurrent stroke
A registered study says what someone planned to measure. It does not say what they found. A number moving is not the same as a life going better. The two are shown apart here.
Felt, but not shown to help. A person notices a change. No study showed it leads anywhere good.
Measured, but not felt. A number moves. The person notices nothing. Both can be true.
Measured, but not shown to matter. A number moves in the good direction. Nobody showed that lives went better.
Matters, but takes years. The result that counts may take longer than anyone would keep watching.
Names that fit none of the three (16)
cardiovascular events
normalization of microalbuminuria
50 reduction in uae from the baseline
low density lipoproteins after 6 weeks
overall percentage of adverse events
n terminal prob type natriuretic peptide at week 8
longitudinal change in residual glomerular filtration rate
interleukin 1 beta
interleukin 6
flow mediated dilatation
safety
These are harms, study-process measures, or names the rules did not recognise. They are shown rather than dropped.
What it would be like to take◇Read from sources, not yet reviewed
How long anything takes
Nine different lengths of time that get confused with each other. None of them is worked out from another.
Before anything is noticed.RNAWiki does not store this separately, and never works it out from another figure on this page.
Before a test result moves.RNAWiki does not store this separately, and never works it out from another figure on this page.
Before performance moves.RNAWiki does not store this separately, and never works it out from another figure on this page.
How long the result was watched.No finished study window is recorded for a study that tested this substance.
How long people took it.How long people actually took it is not stored. The study window is not the same thing.
How long people were followed.Follow-up length is not stored separately. It is never read off the study window, which would be a different thing.
How fast the body clears it. 6 hours hours
Read from the label, which states: “Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.”
How long effects linger.RNAWiki does not store this separately, and never works it out from another figure on this page.
Beyond the studies. Nothing is recorded about the long term.
The longest finished study sets the edge of what anyone measured.
A study window is not how long people took it, and neither is how long they were followed. Where RNAWiki holds only one of the three, it shows one.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
Valsartan tablets are an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Treatment of heart failure (NYHA class II-IV); valsartan tablets significantly reduced hospitalization for heart failure.
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On pediatric, the label states: “The antihypertensive effects of valsartan have been evaluated in a clinical study in pediatric patients from 6-16 years of age [see Clinical Studies (14.1) ].”
US prescribing information · 9402b022-5809-4251-dfef-54f6ef5723fe · read 2026-08-30
On older people, the label states: “In the controlled clinical trials of valsartan, 1,214 (36.2%) hypertensive patients treated with valsartan were ≥65 years and 265 (7.9%) were ≥75 years.”
US prescribing information · 9402b022-5809-4251-dfef-54f6ef5723fe · read 2026-08-30
On people who are pregnant, the label states: “Risk Summary Valsartan can cause fetal harm when administered to a pregnant woman.”
US prescribing information · 9402b022-5809-4251-dfef-54f6ef5723fe · read 2026-08-30
On people who are breastfeeding, the label states: “Risk Summary There is no information regarding the presence of valsartan in human milk, the effects on the breastfed infant, or the effects on milk production.”
US prescribing information · 9402b022-5809-4251-dfef-54f6ef5723fe · read 2026-08-30
On people with reduced liver function, the label states: “No dose adjustment is necessary for patients with mild-to-moderate liver disease.”
US prescribing information · 9402b022-5809-4251-dfef-54f6ef5723fe · read 2026-08-30
On people with reduced kidney function, the label states: “Safety and effectiveness of valsartan in patients with severe renal impairment (glomerular filtration rate less than 30 mL/min/1.73 m 2 ) have not been established.”
US prescribing information · 9402b022-5809-4251-dfef-54f6ef5723fe · read 2026-08-30
Where the result stopped carrying
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied for a different goal
The studies measured something else entirely.
On this record: Some registered studies measured things that match no goal on this page.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
A different form was studied
The studied form is not the form on the shelf.
On this record: This record is linked to 1 related forms. Evidence does not carry across all of them.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (9)
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Prescription only
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Oral
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Suppression classes recorded: S3, S6.
No source is stored against this line.
What is in the pack
Sold as tablet, capsule, solution, capsule, pellets, given by the oral route.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold and what that means for what is in the pack.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take∅Nothing found in the sources checked
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
∅Nothing found in the sources checked
No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.
The sources listed were searched and held nothing. That is not the same as nothing existing.
Reports sent to a regulator
These are reports people sent to a regulator. They do not show the medicine caused the reaction.
Nobody counted how many people took the medicine and reported nothing.
The same event can be reported more than once, and many reports are incomplete.
News coverage, lawsuits and new warnings change how often people report.
A count is not a rate and not a risk.
Valsartan appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 16224 reaction mentions were counted. One report can name several reactions.
wrong technique in product usage process — 862 reaction mentions
open-targets-adr · recorded 2026-06-24 · a recorded source, not a stored snapshot
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Oral
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing further is recorded about which forms are sold.
No source is stored against this line.
What is recorded as being sold
458 products list this as an active ingredient in the United States drug directory. 163 of them contain it and nothing else.
FDA National Drug Code directory · 72336-910 · read 2026-08-29
They are sold as pellet, powder, solution, tablet and tablet, film coated, taken oral.
FDA National Drug Code directory · 72336-910 · read 2026-08-29
The regulator's established pharmacologic class for it is angiotensin 2 receptor antagonists [moa] and angiotensin 2 receptor blocker [epc].
FDA National Drug Code directory · 72336-910 · read 2026-08-29
168 published labels name it as an active ingredient. 64 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · 4f88efbb-3718-43a1-91d4-da5943ccfca1 · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · 4f88efbb-3718-43a1-91d4-da5943ccfca1 · read 2026-08-29
valsartan is oral at 3 DOSAGE FORMS AND STRENGTHS Valsartan tablets, USP are available as: 40 mg tablets are yellow colored, capsule shaped, biconvex, film coated tablets, with a scoreline on one side, debossed with 'C' on one side of score…, recorded as fda label in effect 2026-08-26 in the United States.
US prescribing information · 9402b022-5809-4251-dfef-54f6ef5723fe · read 2026-08-30
Recorded price in US: 0.08915–0.16484 USD per one unit as the pricing file counts it — a tablet, capsule, patch or single item, across 68 priced products whose strengths and pack forms differ, as of 2026-08-26, paid by retail pharmacies buying the product, as surveyed by the Centers for Medicare & Medicaid Services. It is not a list price, an insurance price, or what anyone pays at a counter..
Recorded source · 2026-08-26 · read 2026-08-28
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
This order is fixed in code and does not count clicks or time on the page.
What is not here
5 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
The path through the body — found nothing in the sources checked.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
Claims that go past the evidence — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
Recorded evidence blocks (14)
Q2
What did Valsartan's largest trial (42269 people) and its longest (18 years) measure?
42269 people in Valsartan's largest registered study, 18 years in its longest registered window, measuring All-cause mortality. ClinicalTrials.gov · 2026-09-01
104 phase4, 60 phase3, 38 phase2, 31 phase1, 21 na, 10 na or unstated, 2 early phase1; NCT02966665; 2026-08. Last human test completed 2026, NCT07341893.
Interpretation These counts include studies where Valsartan was a comparison treatment, a background treatment or an exposure in an observational study, and the longest window may be a planned end date. Trial roles have not yet been classified for this record.
Show the evidence
phase4
104
phase3
60
phase2
38
phase1
31
na
21
na or unstated
10
2 more recorded rows
early phase1
2
Last recorded human testNCT07341893
2026-03-30
recorded 2026-09-01 · last checked 2026-09-04
Q3
From mouse to human: where has Valsartan shown lifespan?
Interpretation All-cause mortality — the recorded outcome words.
Show the evidence
mouse
mechanism-only
rat
lifespan
dog
lifespan
humanNCT02735707
lifespan; All-cause mortality; 257
recorded 2026-09-01 · last checked 2026-09-04
Q4
27 of Valsartan's trials stopped: safety, futility/efficacy, accrual/recruitment, funding/business, other?
safety (2), futility/efficacy (1), accrual/recruitment (9), funding/business (5) and other (10): Valsartan's stop wording, clustered. ClinicalTrials.gov · 2026-09-01
"The number of actual events was extremely low. We extended the study period, but it was still not enough. Also, many patients were loss of follow up."; 27 of 257 registered studies
Show the evidence
Trial
NCT00140790
terminated; "The number of actual events was extremely low. We extended the study period, but it was still not enough. Also, many patients were loss of follow up."
NCT00343499
terminated; "Inability to recruit"
NCT00424801
terminated; "Due to recent findings relating MRI contrast to nephrogenic systemic fibrosis"
NCT00738972
terminated; "Study terminated early due to sample size, not possible to perform further statistical analysis."
NCT00878969
terminated; "insufficient enrollment and retention"
NCT01400256
withdrawn; "lack of recruitment/patient population"
14 further recorded trials
NCT01432106
withdrawn; "Novartis terminated all projects involving aliskiren. Findings of the DMC overseeing the ALTITUDE clinical trial found a higher incidence of adverse events."
NCT01805804
terminated; "Recall of some valsartan preparations. 88 patients enrolled and completed the observation. All patients are in continuous observation and are well."
NCT02058823
terminated; "budget constraints"
NCT02606279
terminated; "Change in study design and inability to recruit participants"
NCT02636283
terminated; "Recruitment"
NCT02787798
terminated; "Today Entresto treatment has marketing authorization and is available for all patients, that is the reason why study was halted prematurely."
NCT02788656
terminated; "Inadequate Recruitment"
NCT03119623
withdrawn; "Lost funding prior to study commencing"
NCT03279861
withdrawn; "protocol change"
NCT03315832
withdrawn; "problem of faisability"
NCT03415906
withdrawn; "Difficulties in recruiting patients"
NCT03508739
suspended; "We do not have active funding at this time."
NCT03686657
withdrawn; "Clinical stage asset and the sponsorship have been acquired by Myopharm Limited."
NCT03738878
terminated; "An alternative study was developed to replace this study."
recorded 2026-09-01 · last checked 2026-09-04
Q5
Human studies of Valsartan used Valsartan 320 mg — over how long?
20 recorded entries; human; also "Valsartan 320 mg", "Diovan 40mg or Diovan 80mg", "valsartan 160 mg"
Show the evidence
human
NCT00171054
Valsartan 320 mg
NCT00190580
Diovan 40mg or Diovan 80mg
NCT00294086
valsartan 160 mg
NCT00294086
valsartan 160 mg BID
NCT00409578
Aliskiren/valsartan 300/320 mg
NCT00413413
Valsartan/amlodipine 80/5 mg
14 more recorded rows
humanNCT00413413
Valsartan 80 mg
humanNCT00413413
Valsartan 160 mg
humanNCT00425373
Valsartan + amlodipine 40/2.5 mg
humanNCT00425373
Valsartan + amlodipine 40/5 mg
humanNCT00425373
Valsartan + amlodipine 80/2.5 mg
humanNCT00425373
Valsartan + amlodipine 80/5 mg
humanNCT00425373
Valsartan 40 mg
humanNCT00437645
Valsartan 160 mg capsules
humanNCT00732069
Valsartan 80mg/d for 2 days followed by 160mg/d for 5 days.
humanNCT00922441
Reference (Valsartan 80 mg) group
humanNCT01001572
Valsartan/amlodipine 160/5 mg
humanNCT01001572
Diovan® 160mg
humanNCT01070043
Amlodipine 5mg/Valsartan 80 mg
humanNCT01425411
Diovan 80 mg
recorded 2026-09-01 · last checked 2026-09-04
Q6
Valsartan's half-life is 6 hours — which schedules were studied?
6 hours, the half-life Valsartan's label states. openfda-label · 9402b022-5809-4251-dfef-54f6ef5723fe · 2026-08-30
bioavailability 25% %.
Show the evidence
half life
6 hours hours; Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
tmax
In heart failure patients, the average time to peak plasma concentration and elimination half-life of valsartan are similar to those observed in healthy volunteers.
bioavailability
25% %; Absolute bioavailability for valsartan is about 25% (range 10% to 35%).
metabolism
Metabolism : The primary metabolite, accounting for about 9% of dose, is valeryl 4-hydroxy valsartan.
recorded 2026-08-30 · last checked 2026-09-04
Q7
Which of 24 hour ambulatory systolic blood pressure at week 8, 50 reduction in uae from the baseline and achieving blood pressure goals did Valsartan's trials measure?
24 hour ambulatory systolic blood pressure at week 8, 50 reduction in uae from the baseline and achieving blood pressure goals lead 40 outcome terms across Valsartan's trials. ClinicalTrials.gov · 2026-09-01
urinary albumin excretion after 30 weeks, systolic blood pressure after 4 weeks, urine protein excretion after 20 weeks, normalization of microalbuminuria, 50 reduction in uae from the baseline and systolic 24 hour blood pressure after 12 weeks follow.
Show the evidence
blood pressure
1
stroke
1
cardiovascular events
1
urinary albumin excretion after 30 weeks
1
systolic blood pressure after 4 weeks
1
urine protein excretion after 20 weeks
1
14 more recorded rows
normalization of microalbuminuria
1
50 reduction in uae from the baseline
1
systolic 24 hour blood pressure after 12 weeks
1
low density lipoproteins after 6 weeks
1
blood pressure less than 140/90 after 14 weeks
1
diastolic blood pressure after 8 weeks
1
sitting diastolic blood pressure after 8 weeks
1
overall percentage of adverse events
1
n terminal prob type natriuretic peptide at week 8
1
mean sitting diastolic blood pressure at trough
1
urinary protein loss whithin 24 hours
1
sitting systolic blood pressure
1
sitting systolic blood pressure from baseline to week 8
1
peripheral edema from baseline to week 8
1
recorded 2026-09-01 · last checked 2026-09-04
Q8
Which of Valsartan's 19 ongoing trials reports first?
All-cause mortality; Change in Limb Blood Flow; latest 2029-12-01
Show the evidence
Trial
NCT02735707
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia"; n 20000; "All-cause mortality"; 2028-02
NCT02966665
": Vascular Function in Health and Disease"; n 420; "Change in Limb Blood Flow"; 2026-08
NCT03535376
"Bariatric Surgery and Pharmacokinetics of Valsartan"; n 12; "Valsartan concentration in blood serum (area under curve (AUC))"; 2026-10
NCT03938389
"The Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose in African Americans"; n 90; "Change from Baseline to 26 weeks in β-cell function (first-phase insulin secretion)"; 2026-06
NCT04055428
"NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals"; n 200; "Change in insulin sensitivity after natriuretic peptide augmentation"; 2027-05-31
NCT04191681
"Safety and Efficacy of ARNI After LVAD ImplanT (SEAL-IT) Study"; n 50; "Incidence of drug discontinuation from drug-related adverse events due to sacubitril-valsartan versus standard-of-care oral vasodilator therapy at 3 months"; 2022-12
13 further recorded trials
NCT04971720
"PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis"; n 160; "Change in mean nocturnal systolic blood pressure"; 2027-01-01
NCT05194111
"Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan"; n 70; "Determine feasibility of recruitment to this pilot trial by evaluating the eligibility requirements among adult age survivors of cancer diagnosed at or before age 39 who have stage B heart failure."; 2028-11-30
NCT05279742
"Enhancing the Natriuretic Peptide System in HFpEF"; n 60; "Change in Plasma ANP"; 2027-04
NCT06053580
"Repurposing Valsartan May Protect Against Pulmonary Hypertension"; n 60; "Six-minute walk distance"; 2027-07-01
NCT06218199
"Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts"; n 80; "Number of participants with recovery from HeartLogic Alert"; 2026-12-31
NCT06643819
"Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A"; n 324; "change from baseline in MASBP(Mean Ambulatory Systolic Blood Pressure)"; 2026-12-31
NCT06771245
"A Phase III Clinical Trial Evaluating the Efficacy and Safety of Valsartan/Levamlodipine (SYH9056) Tablets In Hypertensive Patients"; n 606; "Absolute change from baseline in mean sitting systolic blood pressure at Week 12"; 2026-10-30
NCT06863987
"A Phase III Clinical Study of Valsartan Oral Solution for the Treatment of Hypertension in Children and Adolescents"; n 342; "Change in mean seated systolic blood pressure (MSSBP) from the end of week 6 to the end of week 8 in the valsartan oral solution group compared to the placebo group."; 2027-12
NCT07139405
"TriGlytza®-01 Versus Metformin in Overweight and Obese Adults With Type 2 Diabetes and Inadequate Glycaemic Control Despite Metformin Therapy"; n 48; "Incidence and severity of treatment-emergent adverse events and changes in clinical safety assessments through Week 16."; 2027-12-30
NCT07331389
"A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin"; n 111; "AUC[0-∞]"; 2026-06-13
NCT07491718
"Manganese-enhanced Magnetic Resonance Imaging in Takotsubo Cardiomyopathy"; n 100; "Left ventricular myocardial manganese uptake."; 2028-08-09
NCT07539298
"Effects of VALsartan On atRIAl Mitral Regurgitation (VALORIA) - Pilot"; n 50; "Mitral leaflet size"; 2029-12-01
NCT07547878
"Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)"; n 64; "On-study retention rate at 6 months"; 2029-03-31
recorded 2026-09-01 · last checked 2026-09-04
Q9
Which running trial of Valsartan could settle insulin sensitivity?
NCT04055428 measures Change in insulin sensitivity after natriuretic peptide augmentation, reading out 2027-05-31.
3 open trials; n 200; "NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals"
Show the evidence
Trial
NCT04055428
"NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals"; n 200; "Change in insulin sensitivity after natriuretic peptide augmentation"; 2027-05-31
NCT06053580
"Repurposing Valsartan May Protect Against Pulmonary Hypertension"; n 60; "Six-minute walk distance"; 2027-07-01
NCT02735707
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia"; n 20000; "All-cause mortality"; 2028-02
Q10
Which 92 trials of Valsartan posted no result?
Posted no result
92 of 92 completed trials
Registrations
NCT00409643, NCT00241137, NCT00241150, NCT00185055, NCT00333489 and NCT01518855, and 86 more
Completion dates
oldest 2004-07; newest 2024-06-28
Show the evidence
Trial
NCT00409643
2004-07
NCT00241137
2005-01
NCT00241150
2005-01
NCT00185055
2005-02
NCT00333489
2005-04
NCT01518855
2005-04
14 further recorded trials
NCT00241098
2005-06
NCT00241124
2005-06
NCT00241072
2005-07
NCT00241085
2005-08
NCT00171353
2005-09
NCT00153023
2005-12
NCT00171041
2006-03
NCT00171080
2006-03
NCT00170924
2006-06
NCT00171574
2006-07
NCT00254475
2006-09
NCT00311740
2006-09
NCT00171028
2006-11
NCT00294086
2007-01
Q11
At the median, Valsartan's trials enrolled 100 people — anything larger?
Median enrolment
100
Largest enrolment
42269
Registered trials counted
257
Q12
What do 16224 spontaneous reports say about Valsartan — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Valsartan appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 16224 reaction mentions were counted: hypotension 3757; dizziness 2480; dyspnoea 2468; cough 1390. open-targets-adr · CHEMBL1069 · 2026-06-24
Show the evidence
hypotension
3757
dizziness
2480
dyspnoea
2468
cough
1390
acute kidney injury
1152
cardiac failure
1142
4 more recorded rows
blood pressure increased
1012
blood creatinine increased
1004
hyperkalaemia
957
wrong technique in product usage process
862
recorded 2026-06-24 · last checked 2026-09-04
Q13
Valsartan and CYP2C9 and OATP1B1: shared by which compounds?
CYP2C9 and OATP1B1 appear in Valsartan's recorded interaction sentences, 1 in all. openfda-label+europepmc · 2026-08-30
Interpretation pharmacokinetics
Show the evidence
CYP2C9pharmacokinetics
In vitro metabolism studies involving recombinant CYP 450 enzymes indicated that the CYP 2C9 isoenzyme is responsible for the formation of valeryl-4-hydroxy valsartan.
recorded 2026-08-30 · last checked 2026-09-04
Q14
Was Valsartan studied with fasting and exercise?
fasting and exercise are named in Valsartan's label sentences: "A clinical trial was performed to demonstrate that the test and reference valsartan/amlodipine formulations were bioequivalent under fasting and postprandial conditions." openfda-label+europepmc · 2026-08-30
2 recorded statements; fasting, exercise
Show the evidence
fasting
A clinical trial was performed to demonstrate that the test and reference valsartan/amlodipine formulations were bioequivalent under fasting and postprandial conditions.
exercise
The placebo effect model was also used as an external control in evaluating Sacubitril/Valsartan and exercise training efficacy.
recorded 2026-08-30 · last checked 2026-09-04
Q15
What is recorded about Valsartan and sirtuin?
"Stabilization of this promoter GQ by the canonical ligand BRACO-19 markedly reduced SIRT3 levels in lung cancer cells, and two clinically approved angiotensin II receptor blockers, candesartan and valsartan, also suppressed cell viability by selectively targeting this GQ motif." — where Valsartan and sirtuin appear together. Europe PMC · pathway abstract search · 2026-05-28
"Stabilization of this promoter GQ by the canonical ligand BRACO-19 markedly reduced SIRT3 levels in lung cancer cells, and two clinically approved angiotensin II receptor blockers, candesartan and valsartan, also suppressed cell viability by selectively targeting this GQ motif."
mTOR
PMID 42193440
"In contrast, combined treatment achieved the most pronounced improvement in contractile performance, attenuated oxidative stress more consistently, reduced expression of TNF-α, IL-1β, IL-6, IL-17, Bax, CASP-3, and CASP-9, favorably modulated JAK2, STAT3, mTOR, and PPARγ expression, and decreased myocardial collagen content. <b>Conclusions:</b> Dual empagliflozin and sacubitril/valsartan therapy…"
PMID 37461345
"Moreover, valsartan also acts by inhibiting or inducing various signalling pathways, such as inducing autophagy <i>via</i> the AKT/mTOR/S6K pathway or inhibiting the TLR/NF-kB pathway."
autophagyPMID 37461345
"Moreover, valsartan also acts by inhibiting or inducing various signalling pathways, such as inducing autophagy <i>via</i> the AKT/mTOR/S6K pathway or inhibiting the TLR/NF-kB pathway."
mTORPMID 38284316
"Molecular docking and molecular dynamics studies were used for in silico assessment of the binding affinity of sacubitril and valsartan towards subunits of mechanistic target of rapamycin complex 1 (mTORC1)."
autophagyPMID 37724955
"Additionally, the combination treatment significantly activated autophagy and reduced the ROS production than valsartan alone."
AMPKPMID 31307032
"Valsartan activated AMPK, which in turn suppressed reactive oxygen species production and consequently attenuated VSMC proliferation and migration."
autophagyPMID 24084854
"Valsartan preconditioning induced autophagy via the AKT/mTOR/S6K pathway, independent of Beclin1."
recorded 2026-05-28 · last checked 2026-09-04
Where it is registeredIdentifiers, relations and other names
Diovan, Prexxartan, Valsartan component of agsav301, Valsartan component of byvalson, Valsartan component of copalia, Valsartan component of copalia-hct, Valsartan component of dafiro, Valsartan component of dafiro-hct, Valsartan component of diovan hct, Valsartan component of entresto, Valsartan component of exforge, Valsartan component of exforge hct
ChEMBL ATC CC BY-SA · ClinicalTrials.gov — US Government work · Europe PMC — metadata only, under the recorded legal gate · Open Targets 26.06 — CC0 · derived from this page's own recorded fields; no external licence · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
✗ required summary fields resolved: 5 required field(s) not terminal: Why people use it, Best-supported result, Most important common problem, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 11 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.